StockTipsArenaBeta

BUY Aurobindo Pharma — HSBC Securities

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byHSBC SecuritiesHorizon: NA (inferred 1 year)22 Jun 2026via NDTV Profit (Live)

Entry₹1,497.8Stated
Target₹1,580
Total upside +5.49% (call closed)
Stop lossNot given
Exit₹1,58029 Jun 2026, 12:06 pm
Target hit+5.49%0.00%upside left
Follow HSBC Securities for new calls(100% target hit, 23 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 11 active Long-term calls on AUROPHARMASee 211 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 5:35 pm IST
8 supporting4 neutral0 opposing
Supports the BUY call (8)

Aurobindo Pharma Ltd has announced the completion of an acquisition.

BSE · Company Update·25 Jun · 3d ago

(opens in new tab)

Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited for Rs. 52 lakhs. The company plans further investm

NSE · Acquisition·25 Jun · 3d ago

(opens in new tab)

Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.

NSE · Press Release·22 Jun · 1w ago

(opens in new tab)

Aurobindo Pharma USA, a subsidiary of Aurobindo Pharma Ltd, has received FTC approval to acquire Lannett Company LLC for $250 million. This acquisition is expected to be immediately accretive to earni

BSE · Company Update·22 Jun · 1w ago

(opens in new tab)

Aurobindo Pharma Ltd has received final US FDA approval for its Tafacitinib tablets in 5 mg and 10 mg strengths. This approval is a significant regulatory milestone for the company's pharmaceutical pr

BSE · Company Update·4 Jun · 3w ago

(opens in new tab)
Neutral / worth noting (4)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from HSBC Securities

Every call and its outcome